Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tolterodine ER 4 mg QD | Drug | |||
| OAB Patient Behavioral Training Material | Behavioral |
| Measure | Description | Time Frame |
|---|---|---|
| Subject satisfaction with treatment at week 16: Percentage of subjects reporting satisfaction with their current OAB treatment using the Patient Perception of Treatment Satisfaction Question |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of subjects reporting satisfaction (including 'very satisfied' and 'a little satisfied') with their current OAB treatment measured by Patient Perception of Treatment Satisfaction | ||
| Percent subjects changed dissatisfied(including'very dissatisfied'and'a little dissatisfied')with OAB week 8 to satisfied(including'very satisfied' and'a little satisfied')with OAB week 16 measured by Patient Perception of Treatment Satisfaction Question |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | United States | |||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Change in mean number of urgency urinary incontinence episodes at weeks 4, 8, 12 and 16 compared with baseline |
| Change in mean number of urgency episodes per day at weeks 4, 8, 12 and 16 compared with baseline (Urgency episode defined as micturition episodes associated with Urinary Sensation Scale rating of greater than or equal to 3). |
| Change in daily urgency micturition rating at weeks 4,8,12 and 16 compared with baseline:Change in mean and sum of Urinary Sensation Scale rating per day |
| Change in mean number of micturition episodes per 24 hour period and per nocturnal period at weeks 4, 8, 12 and 16 compared with baseline. Means will be based on five dairy days. The following micturition episode parameters will be assessed: |
| Total micturitions: total number of micturition episodes per time period (24 hour or nocturnal) |
| OAB micturition: Number of OAB mictruition episodes per time period (24 hour or nocturnal). OAB micturition defined as number of micturition episodes associated with Urinary Sensation Scale ratting of greater than or equal to 3 |
| Severe OAB micturitions in subjects with severe OAB micturition at baseline: Number of severe OAB micturition episodes per time period (24 hour or nocturnal). |
| Severe OAB micturition episodes defined as number of micturitions associated with a Urinary Sensation Scale rating of greater than or equal to 4 |
| Change in Patient Perception of Bladder Condition (PPBC) at weeks 8 and 16 compared with baseline |
| Change in Patient Perception of Urgency Scale (PPUS) at weeks 8 and 16 compared with baseline |
| Change in total Health Related Quality of Life (HRQoL) for Overactive Bladder Questionnaire (OAB-q) and change in scores for each individual domain (symptom bother, coping, concern, sleep, and social function) at weeks 8 and 16 compared with baseline |
| Reasons for treatment withdrawal. |
| Adverse events during the 16 week treatment period |
| Sun Lakes |
| Arizona |
| United States |
| Pfizer Investigational Site | Little Rock | Arkansas | United States |
| Pfizer Investigational Site | Beverly Hills | California | United States |
| Pfizer Investigational Site | Buena Park | California | United States |
| Pfizer Investigational Site | Mission Viejo | California | United States |
| Pfizer Investigational Site | Modesto | California | United States |
| Pfizer Investigational Site | Oceanside | California | United States |
| Pfizer Investigational Site | Paramount | California | United States |
| Pfizer Investigational Site | Sacramento | California | United States |
| Pfizer Investigational Site | Torrance | California | United States |
| Pfizer Investigational Site | Tustin | California | United States |
| Pfizer Investigational Site | Colorado Springs | Colorado | United States |
| Pfizer Investigational Site | Wheat Ridge | Colorado | United States |
| Pfizer Investigational Site | Hallandale | Florida | United States |
| Pfizer Investigational Site | Orlando | Florida | United States |
| Pfizer Investigational Site | Wellington | Florida | United States |
| Pfizer Investigational Site | Woodstock | Georgia | United States |
| Pfizer Investigational Site | Libertyville | Illinois | United States |
| Pfizer Investigational Site | Mattoon | Illinois | United States |
| Pfizer Investigational Site | Newton | Kansas | United States |
| Pfizer Investigational Site | Milford | Massachusetts | United States |
| Pfizer Investigational Site | Manchester | Missouri | United States |
| Pfizer Investigational Site | St Louis | Missouri | United States |
| Pfizer Investigational Site | Westhampton | New Jersey | United States |
| Pfizer Investigational Site | Albuquerque | New Mexico | United States |
| Pfizer Investigational Site | Albany | New York | United States |
| Pfizer Investigational Site | Endwell | New York | United States |
| Pfizer Investigational Site | Garden City | New York | United States |
| Pfizer Investigational Site | Poughkeepsie | New York | United States |
| Pfizer Investigational Site | The Bronx | New York | United States |
| Pfizer Investigational Site | Greensboro | North Carolina | United States |
| Pfizer Investigational Site | Hickory | North Carolina | United States |
| Pfizer Investigational Site | Raleigh | North Carolina | United States |
| Pfizer Investigational Site | Canton | Ohio | United States |
| Pfizer Investigational Site | Zanesville | Ohio | United States |
| Pfizer Investigational Site | Norman | Oklahoma | United States |
| Pfizer Investigational Site | Abington | Pennsylvania | United States |
| Pfizer Investigational Site | Bala-Cynwyd | Pennsylvania | United States |
| Pfizer Investigational Site | Camp Hill | Pennsylvania | United States |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | United States |
| Pfizer Investigational Site | Williamsport | Pennsylvania | United States |
| Pfizer Investigational Site | Mt. Pleasant | South Carolina | United States |
| Pfizer Investigational Site | Simpsonville | South Carolina | United States |
| Pfizer Investigational Site | Bartlett | Tennessee | United States |
| Pfizer Investigational Site | Johnson City | Tennessee | United States |
| Pfizer Investigational Site | New Tazewell | Tennessee | United States |
| Pfizer Investigational Site | Houston | Texas | United States |
| Pfizer Investigational Site | Provo | Utah | United States |
| Pfizer Investigational Site | Mountlake Terrace | Washington | United States |
| Pfizer Investigational Site | Spokane | Washington | United States |
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| ID | Term |
|---|---|
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068737 | Tolterodine Tartrate |
| ID | Term |
|---|---|
| D010665 | Phenylpropanolamine |
| D011412 | Propanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D020005 | Propanols |
| D000588 | Amines |
| D001559 | Benzhydryl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D003408 | Cresols |
| D010636 | Phenols |
Not provided
Not provided